Table III.
Results of an adjusted indirect comparison between the efficacy of infliximab and adalimumab or infliximab and golimumab
| Variable | 6–8 weeks | 52–54 weeks | ||
|---|---|---|---|---|
| Clinical response (RR (95% CI)) | Clinical remission (RR (95% CI)) | Clinical response (RR (95% CI)) |
Clinical remission (RR (95% CI)) | |
| Infliximab 5 mg vs. adalimumab 160/80 mg | ||||
| Infliximab [37], [38] vs. adalimumab [31], [32], [39–41] | 1.47 (1.15–1.87) p = 0.0022 | 2.35 (0.96–5.81) p > 0.05 |
1.39 (0.82–2.33) p > 0.05 |
1.03 (0.52–2.04) p > 0.05 |
| Infliximab 5 mg vs. adalimumab 80/40 mg | ||||
| Infliximab [37], [38] vs. adalimumab [31], [32] | 1.71 (1.28–2.28) p = 0.0002 |
3.27 (1.25–8.57) p = 0.0158 |
NA | NA |
| Infliximab 5 mg vs. adalimumab 40 mg | ||||
| Infliximab [37], [38] vs. adalimumab [31], [32], [39–41] | NA | NA | 1.36 (0.83–2.22) p > 0.05 |
0.91 (0.49–1.69) p > 0.05 |
| Infliximab 5 mg vs. golimumab 200/100 mg | ||||
| Infliximab [37], [38] vs. golimumab [42] | 1.18 (0.88–1.59) p > 0.05 |
1.34 (0.51–3.52) p > 0.05 |
NA | NA |
| Infliximab 5 mg vs. golimumab 100 mg | ||||
| Infliximab [37], [38] vs. golimumab [43] | NA | NA | 1.44 (0.87–2.36) p > 0.05 |
1.23 (0.64–2.33) p > 0.05 |
| Infliximab 5 mg vs. golimumab 50 mg | ||||
| Infliximab [37], [38] vs. golimumab [43] | NA | NA | 1.52 (0.92–2.51) p > 0.05 |
1.47 (0.76–2.84) p > 0.05 |